Cipla News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Cipla Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 3
Author: Deven Choksey

Keep track of all breaking news and updates on Cipla from all sources in a single place.

Load latest

Cipla Ltd.

13 Oct 2025

1498.90

0.13%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Earnings Conference Call to be held on 30th October, 2025.

pdf

Cipla Ltd.

24 Sep 2025

1498.90

0.13%

Board Meeting

Cipla Ltd - 500087 - Board Meeting Intimation for Meeting Of The Board Of Directors Of …

BSE India

Cipla Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2025 ,inter alia, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended 30th September, 2025

pdf

Cipla Ltd.

12 Sep 2025

1498.90

0.13%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

In compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 12th September, 2025 has allotted 11,621 fully paid up equity shares of INR 2 each pursuant to exercise of employee stock options/stock appreciation rights under the Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scehem 2021

pdf

Cipla Ltd.

12 Sep 2025

1498.90

0.13%

Company Update

Cipla Ltd - 500087 - Intimation Under Regulation 30 Read With Schedule III Of The SEBI …

BSE India

Please find attached disclosure on ESG rating

pdf

Cipla Ltd.

10 Sep 2025

1498.90

0.13%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein mention the schedule of Analyst / Institutional Investor Meeting with the Company.

pdf

Cipla Ltd.

08 Sep 2025

1498.90

0.13%

Growth outlook intact despite near-term headwinds

Hold: Cipla Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by +0.9%/-5.2%, as we factor in lower revenue on account of ramp down of Revlimid portfolio and ongoing price erosion in the US market, higher depreciation and amortization expense, offset by higher other income.

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

05 Sep 2025

1498.90

0.13%

Cipla launches Huena, India's first non-antibiotic drug to fight UTI

Business Standard

Drug firm Cipla on Friday said it has introduced a non-antibiotic treatment for patients suffering from recurrent urinary tract infections. The company has launched Methenamine Hippurate under the brand name HUENA. This marks a significant step forward for the company in its fight against anti-microbial resistance as it becomes the first to introduce such treatment in India, the Mumbai-based drugmaker said in a statement. Urinary tract infections (UTIs) are the second most common reason for antibiotic use in India, with infection cases doubling over the last 30 years. Women are more susceptible to UTIs, which account for 15 per cent of overall antibiotic prescriptions. Methenamine Hippurate offers an effective, non-antibiotic alternative for preventing UTIs by targeting bacteria in the bladder and urinary tract. Studies show it is as effective as long-term, low-dose antibiotic therapy for UTI prevention, with lower costs and no risk of antibiotic resistance. "We believe this...

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

02 Sep 2025

1498.90

0.13%

India, RoW biz to stay steady, US drug pipeline - the next trigger

Buy: Cipla Ltd.

Target

Sharekhan

Cipla has robust domestic and global product pipelines. US product pipeline to be healthy and will be key to driving growth from H2FY26E and contribute significantly from FY27E onwards.